Changes in retinal layer thickness following optic neuritis may predict the course of relapsing multiple sclerosis
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Aug. 18, 2022 (HealthDay News) -- Retinal layer thinning after optic neuritis (ON) may be useful as a marker of future relapse remission in relapsing multiple sclerosis (MS), according to a study published online Aug. 2 in Neurology.
Gabriel Bsteh, P.D., M.D., Ph.D., from the Medical University of Vienna, and colleagues used data from the Vienna MS database to investigate whether retinal thinning after ON is associated with relapse remission after subsequent non-ON relapses. The analysis included 167 MS patients with an episode of acute ON and available spectral-domain optical coherence tomography (OCT) scans within 12 months before ON onset (OCTbaseline), within one week after ON onset (OCTacute), and at three to six months of follow-up (OCTfollow-up).
The researchers found that during a mean of 3.4 years of follow-up after the ON episode, 36.5 percent of patients had at least one relapse that showed incomplete remission. Incomplete remission of non-ON relapse was associated with macular ganglion-cell-and-inner-plexiform-layer thinning both from OCTbaseline to OCTfollow-up and from OCTacute to OCTfollow-up (odds ratio [OR], 2.4 per 5 µm), independently explaining 29 and 27 percent of variance, respectively. Change in retinal thinning in the peripapillary retinal nerve fiber layer from OCTbaseline to OCTfollow-up also was associated with incomplete relapse remission (OR, 1.9 per 10 µm), which independently accounted for 22 percent of variance.
"In retinal layer thickness, we have found a new biomarker that represents a window to the brain, as it were," Bsteh said in a statement.
Several authors disclosed financial ties to pharmaceutical companies.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles